Table 5.

In each of 11 experiments, 20 top-ranked significant treatments with compounds whose downregulated genes significantly coincide with some genes selected for each experiment were identified. Thus, treatments with the following compounds are most frequently ranked within top 20.

Exp.	#		(i)	(ii)	(iii)	(iv)	(v)	(vi)	(vii)	(viii)
1	(232)	OL	10/85				16/154
	[129]	adj P-value	$6.14\times {10}^5$				$6.59\times {10}^7$
2	(711)	OL
	[329]	adj P-value
3	(747)	OL
	[417]	adj P-value
4	(441)	OL	16/85		14/105	15/109		16/144
	[67]	adj P-value	$8.56\times {10}^7$		$1.15\times {10}^4$	$5.10\times {10}^5$		$1.56\times {10}^4$
5	(123)	OL		17/141			12/154
	[219]	adj P-value		$2.87\times {10}^{13}$			$2.26\times {10}^7$
6	(292)	OL			13/105					19/137
	[132]	adj P-value			$9.69\times {10}^6$					$3.04\times {10}^9$
7	(246)	OL	9/85				12/154
	[61]	adj P-value	$1.41\times {10}^3$				$8.88\times {10}^4$
8	(873)	OL	30/85	46/141					35/162
	[255]	adj P-value	$1.19\times {10}^{15}$	$1.62\times {10}^{23}$					$5.21\times {10}^{12}$
9	(119)	OL	9/85	11/141		8/109		8/144	8/162	12/137
	[74]	$6.25\times {10}^6$	$3.48\times {10}^6$		$3.50\times {10}^4$		$1.45\times {10}^3$	$2.33\times {10}^3$	$2.76\times {10}^7$
10	(104)	OL	9/85		9/105	9/109		10/144		12/137
	[155]	adj P-value	$1.87\times {10}^6$		$4.96\times {10}^6$	$6.22\times {10}^6$		$4.96\times {10}^6$		$7.01\times {10}^8$
11	(120)	OL		10/141					9/162
	[127]	adj P-value		$4.74\times {10}^5$					$5.26\times {10}^4$

(i) LJP005_BT20_24H-GSK-1059615-3.33; (ii) LJP005_HS578T_24H-LDN-193189-10; (iii) LJP005_MCF10A_24H-GSK-1059615-10; (iv) LJP006_BT20_24H-WYE-125132-10; (v) LJP006_HS578T_24H-afatinib-10; (vi) LJP006_MCF10A_24H-PI-103-10; (vii) LJP007_HT29_24H-PD-0325901-0.12; and (viii) LJP009_HEPG2_24H-chelerythrine_chloride-10. #: (numbers): genes; [numbers]: compounds. Upper rows in each exp: OL, overlaps, (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.